ELOXX PHARMACEUTICALS, INC. Retained Earnings
ELOXX PHARMACEUTICALS, INC. (ELOX) had Retained Earnings of -$308.84 million as of 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-09-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$308.84M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$304.33M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$300.58M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$294.58M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$308.84M S-1 · filed 2026-09-11 | |
| 2026-03-31 | -$304.33M S-1/A · filed 2026-06-04 | |
| 2025-12-31 | -$300.58M S-1 · filed 2026-09-11 | |
| 2024-12-31 | -$294.58M S-1 · filed 2026-09-11 | |
| 2023-12-31 | -$291.44M S-1 · filed 2026-09-11 | |
| 2023-09-30 | -$288.55M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$284.96M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | -$280.62M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$274.39M 10-Q · filed 2023-11-13 | |
| 2022-09-30 | -$268.07M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$260.56M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$249.94M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | -$238.32M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$226.23M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | -$216.35M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$180.29M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | -$171.60M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$165.47M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | -$158.85M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$150.97M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | -$137.02M 10-K · filed 2021-03-12 | |
| 2019-09-30 | -$125.39M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | -$112.51M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | -$98.06M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$86.14M 10-K · filed 2020-03-06 | |
| 2018-09-30 | -$72.12M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$60.96M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | -$47.55M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$38.96M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$123.21M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | -$121.82M 10-Q · filed 2017-11-14 | |
| 2017-03-31 | -$119.45M 10-Q · filed 2017-05-22 | |
| 2016-12-31 | -$17.75M 10-K · filed 2018-03-16 | -$117.38M 10-Q · filed 2017-02-10 |
| 2016-09-30 | -$116.57M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | -$115.63M 10-K · filed 2017-10-13 | |
| 2015-06-30 | -$107.18M 10-K · filed 2016-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |